Dermisonics, Inc.
Dermisonics, Inc.: Dermisonics, Inc Recruits Patients To Proceed With Human Pilot Trial-2 On U-Strip™ Ultrasonic Insulin Delivery System For Type-2 Diabetics
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Dermisonics, Inc Recruits Patients To Proceed With Human Pilot Trial-2 On
U-Strip™ Ultrasonic Insulin Delivery System For Type-2 Diabetics
Irvine, CA — April 6, 2006 — Dermisonics, Inc. (OTC Bulletin Board:
DMSI.OB / Frankfurt: FQC), a medical device company focused on the
development of painless, needle-free drug-delivery technology, has begun
recruiting recipients to proceed with a planned Human Pilot Trial-2 on its
U-Strip™ delivery system for use with insulin. This phase is being carried
out on an initial group of Type-2 adult diabetics, which the Company
believes represents the larger population of diabetics who could
immediately benefit from this technology.
The U-Strip is a patented electronic system that uses a specialized form of
ultrasound waves to enhance the delivery of drugs through the skin and into
the bloodstream from a specially modified patch.
This clinical trial will test the Company’s patented U-Strip ultrasonically
assisted transdermal drug-delivery technology versus insulin pump
technology. The goal is to deliver insulin via the U-Strip Insulin Patch up
to one unit per hour, mirroring the exact delivery rate of a conventional
insulin pump. This trial, to be conducted in Media, Pennsylvania under the
direction of Rex Kessler, MD, will compare the invasive insulin pump to the
delivery profile of the non-invasive U-Strip Insulin Patch over a five-hour
test period.
Recruiting of volunteers began in April 2006 for the trials, which are
slated to begin after the initial group of volunteer patients has completed
the selection examination and enrollment process. The Company has already
completed trial preparations including site selection, monitoring logistics
and insurance bonding to cover trial participants. These preliminary steps
clear the way for the trial to begin immediately following recruitment.
Inventor of Dermisonics’ technology and Executive VP, Bruce Redding states,
“Dermisonics has chosen to start the clinical trial Human Pilot-2 with
Type-2 diabetics because these recipients need a more regulated and
consistent insulin dosing program than is available with ordinary
medication. The data from this trial gives Dermisonics the data it needs to
advance to a clinical trial on type-1 diabetics and children suffering
Type-1 diabetes.” Redding adds, “The U-Strip drug-delivery technology
offers a totally non-invasive insulin delivery regimen – no-needles, but
also importantly – a more uniform insulin dosing schedule than is
currently available with either hypodermic needle injection, insulin pumps
or type-2 medications.”
About Dermisonics, Inc.
Dermisonics is an intellectual property company and technology incubator
that is primarily focused on the ongoing development, testing and eventual
commercialization of its active transdermal patch, called the U-Strip, that
has been designed to facilitate the efficient and needle-free delivery of
drugs with large molecular structures such as Insulin into the bloodstream.
The Company has also developed other portable ultrasonic systems for
applications in the medical (Antiseptic Wand) and skin care (U-Wand)
fields.
For additional information see www.dermisonics.com
North American Investor Relations Contact:
International Market Trend
Toll-Free North America
1-877-676-4447
European Investor Relations Contact:
Michael Drepper
Phone: +49-621-430-6130
Toll free hot line: 0800 0000754
investor-germany@dermisonics.com
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although the
Company believes that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are reasonable, it
can give no assurance that such expectations and assumptions will prove to
have been correct. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to
numerous factors and uncertainties, including but not limited to adverse
economic conditions, intense competition, lack of meaningful research
results, entry of new competitors and products, adverse federal, state and
local government regulation, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, technological obsolescence of the
Company’s products, technical problems with the Company’s research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible acquisition
of new businesses or that result in operating losses or that do not
perform as anticipated, unanticipated losses, the possible fluctuation and
volatility of the Company’s operating results, financial condition and
stock price, losses incurred in litigating and settling cases, dilution in
the Company’s ownership of its business, adverse publicity and news
coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other
specific risks. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s most recent Form 10-QSB
and Form 10-KSB filings with the Securities and Exchange Commission.
(c)DGAP 07.04.2006
—————————————————————————
language: English
emitter: Dermisonics, Inc.
Dermisonics, Inc.
19428-2977 West Conshohocken, Pa. Vereinigte Staaten von Amerika
phone: +1 610-941-2780
fax: +1 610-941-2990
email: bruce.haglund@dermisonics.com
WWW: dermisonics.com
ISIN: US24983U1043
WKN: A0DK4Y
indexes:
stockmarkets: Freiverkehr in Berlin-Bremen; Open Market in Frankfurt
End of News DGAP News-Service
—————————————————————————
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden